A clinical trial showed that 21 percent of participants achieved complete remission.

Daurismo (glasdegib) plus chemotherapy improved overall survival in clinical trial.

NK cells are “first responders” that rapidly detect and attack virus-infected cells and tumor cells, and can also help prevent metastasis.

The study used two FDA-approved drugs to the pre-leukemic cells while leaving healthy stem cells alone.

Trials for head and neck cancer, pancreatic cancer, acute myeloid leukemia and myelodysplastic syndrome, among others, will receive funding.

Edwin Alyea, MD, and Don Lewis, who received a stem cell transplant in 2014 to treat his acute myeloid leukemia, explain the procedure.

Tibsovo led to complete remission in some people with acute myeloid leukemia.